Defense Advanced Research Projects Agency Awards AnaptysBio, Inc. up to $1.5 Million to Generate High Affinity Thermally Stable Antibodies

SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has been awarded a contract by the Defense Advanced Research Projects Agency (DARPA), to use its proprietary somatic hypermutation (SHM) technology platform to generate novel high affinity thermally stable antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats.

Back to news